{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:00:48Z","timestamp":1783562448911,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017964","name":"Tianjin Municipal Health Commission","doi-asserted-by":"publisher","award":["(TJWJ2023ZD003"],"award-info":[{"award-number":["(TJWJ2023ZD003"]}],"id":[{"id":"10.13039\/100017964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-NCJH202201-0027, Y-2022YMJN\/MS-0001"],"award-info":[{"award-number":["Y-NCJH202201-0027, Y-2022YMJN\/MS-0001"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has demonstrated clinical potential in treating relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL); however, enhancing its therapeutic efficacy remains a significant challenge. To this end, bridging therapy with Brutonyg tyrosine kinase inhibitors (BTKi), such as ibrutinib or zanubrutinib, is being investigated as a strategy to improve treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>In this retrospective analysis, we assessed the impact of different durations of BTKi bridging therapy prior to anti-CD19 CAR-T cell infusion in 33 patients with R\/R DLBCL. Patients meeting predefined eligibility criteria, including the presence of at least one high-risk prognostic factor. These 33 patients were stratified into two groups based on the duration of BTKi exposure: \u22652 months versus &amp;lt;2 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The R\/R DLBCL patients receiving BTKi for \u22652 months demonstrated a higher overall response rate than the patients receiving BTKi for &amp;lt;2 months. There was no statistically significant differences in progression free survival (PFS) or overall survival (OS) between the two groups. Exploratory analyses suggested potential biomarkers for BTKi bridging efficacy, including modulation of nicotinamide phosphoribosyltransferase (NAMPT) and programmed cell death protein 1 (PD-1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prolonged BTKi bridging might improve the overall response to CAR-T cell therapy in patients with R\/R DLBCL, despite the initial disparities. However, the risk of hematological toxicity associated with extended BTKi use requires attention. Further investigations are essential to validate and translate these observations into clinical practice, thus highlighting the need for further research in this area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.chictr.org.cn\/showproj.aspx?proj=33185<\/jats:ext-link>\n                      , ChiCTR1800019622\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1674235","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:40:24Z","timestamp":1770360024000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed\/refractory DLBCL"],"prefix":"10.3389","volume":"17","author":[{"given":"Jia","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large b-cell lymphoma and indolent b-cell Malignancies can be effectively treated with autologous t cells expressing an anti-cd19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"Kte-x19 car t-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel car t-cell therapy in refractory large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large b-cell lymphomas (transcend nhl 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (zuma-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2104426","article-title":"Enriched circulating and tumor-resident TGF-\u03b2+ regulatory B cells in patients with melanoma promote FOXP3+ Tregs","volume":"11","author":"Harris","year":"2022","journal-title":"Oncoimmunology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","article-title":"Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological Malignancies","volume":"11","author":"Wang","year":"2023","journal-title":"biomark Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3140","article-title":"Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment","volume":"28","author":"Autio","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (nampt) promotes m2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0839","article-title":"Clinical and biological subtypes of b-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.970553","article-title":"Review of various NAMPT inhibitors for the treatment of cancer","volume":"13","author":"Wei","year":"2022","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28041897","article-title":"Anticancer activities of novel nicotinamide phosphoribosyltransferase inhibitors in hematological Malignancies","volume":"28","author":"Biniecka","year":"2023","journal-title":"Molecules"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14638","article-title":"Synergistic effect of ibrutinib and cd19 car-t cells on raji cells in vivo and in vitro","volume":"111","author":"Liu","year":"2020","journal-title":"Cancer Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05255-w","article-title":"Efficacy and safety-related factors of btk inhibitors as a bridge to car-t therapy in r\/r fl","volume":"102","author":"Ye","year":"2023","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14915","article-title":"Ibrutinib improves the efficacy of anti-cd19-car t-cell therapy in patients with refractory non-hodgkin lymphoma","volume":"112","author":"Liu","year":"2021","journal-title":"Cancer Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"Astct consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood marrow transplantation: J Am Soc Blood Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of zuma-1: A multicenter study of kte-c19 anti-cd19 car t cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol therapy: J Am Soc Gene Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor t cells in refractory b-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-1527","article-title":"The addition of the btk inhibitor ibrutinib to anti-cd19 chimeric antigen receptor t cells (cart19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor t-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/Cji.0000000000000307","article-title":"Antitumor potency of an anti-cd19 chimeric antigen receptor t-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J Immunotherapy"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01286-0","article-title":"Btk inhibitors and car t-cell therapy in treating mantle cell lymphoma-finding a dancing partner","volume":"24","author":"Munoz","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.962552","article-title":"Effects of ibrutinib on t-cell immunity in patients with chronic lymphocytic leukemia","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of itk driving a th1-selective pressure in t lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases t cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci89756","article-title":"Ibrutinib treatment improves t cell number and function in cll patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrclinonc.2017.124","article-title":"Haematological cancer: After ibrutinib, car t cells induce responses","volume":"14","author":"Romero","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of cd19-targeted car t cells with concurrent ibrutinib for cll after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2023.10.004","article-title":"Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor t-cell therapy for relapsed\/refractory diffuse large b-cell lymphoma","volume":"44","author":"Lu","year":"2023","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1814535","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1674235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:27:45Z","timestamp":1773059265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1674235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1674235"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1674235","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"article-number":"1674235"}}